Anil Singhal is currently the Vice President of AbbVie and Head of AbbVie Biotherapeutics Inc (ABR). ABR was established as an independent biotech arm of AbbVie, responsible for developing an early oncology pipeline. Prior to this role, Anil was Divisional Vice President of Strategic Program Office at Abbott/AbbVie responsible for the optimization of late stage (post PoC) pharmaceutical pipeline. Previously, he headed the clinical development group at the Abbott Redwood City site and oversaw the ongoing development of two Ph 3 programs, daclizumab in multiple sclerosis and elotuzumab in multiple myeloma. Prior to the acquisition by Abbott, he was responsible for the clinical development of all oncology programs including elotuzumab at Facet. Anil has held senior positions in different US, Japanese and German pharmaceutical/ biotechnology companies for more than two decades and has led many cross-functional development teams (preclinical to Phase 3) resulting in the approval of different diagnostic and therapeutic products in oncology and auto-immune diseases. Prior to his industry roles, he was assistant research professor at the Mount Sinai School of Medicine, and concurrent with his industry role, he was affiliate associate professor at the University of Washington.